Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
skin and connective tissue diseases | D017437 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
breast neoplasms | EFO_0003869 | D001943 | C50 |
Expiration | Code | ||
---|---|---|---|
TALAZOPARIB TOSYLATE, TALZENNA, PFIZER | |||
2026-06-20 | I-920 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 21 | 14 | 1 | — | 4 | 33 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 11 | 15 | 1 | — | 3 | 26 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 8 | 6 | 2 | — | — | 15 |
Prostatic neoplasms | D011471 | — | C61 | 7 | 8 | 1 | — | — | 14 |
Non-small-cell lung carcinoma | D002289 | — | — | 3 | 2 | 1 | — | — | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Triple negative breast neoplasms | D064726 | — | — | 7 | 10 | — | — | — | 14 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 4 | 2 | — | — | — | 5 |
Myeloid leukemia acute | D015470 | — | C92.0 | 5 | 2 | — | — | — | 5 |
Fallopian tube neoplasms | D005185 | — | — | 4 | 1 | — | — | — | 5 |
Castration-resistant prostatic neoplasms | D064129 | — | — | 3 | 2 | — | — | 1 | 5 |
Endometrial neoplasms | D016889 | EFO_0004230 | — | 2 | 3 | — | — | — | 4 |
Colorectal neoplasms | D015179 | — | — | 3 | 2 | — | — | — | 4 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 2 | 3 | — | — | — | 3 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | 1 | — | — | — | 2 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 2 | 1 | — | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Small cell lung carcinoma | D055752 | — | — | 3 | — | — | — | — | 3 |
Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
Uterine cervical neoplasms | D002583 | HP_0030159 | — | 1 | — | — | — | — | 1 |
Vaginal neoplasms | D014625 | — | C52 | 1 | — | — | — | — | 1 |
Mesothelioma | D008654 | — | C45 | 1 | — | — | — | — | 1 |
Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 1 | — | — | — | — | 1 |
Mantle-cell lymphoma | D020522 | — | C83.1 | 1 | — | — | — | — | 1 |
Ovarian epithelial carcinoma | D000077216 | — | — | 1 | — | — | — | — | 1 |
Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 1 | — | — | — | — | 1 |
Drug common name | Talazoparib |
INN | talazoparib |
Description | Talazoparib, sold under the brand name Talzenna, is an anti-cancer medication used for the treatment of breast cancer and prostrate cancer. It is an orally available poly ADP ribose polymerase PARP inhibitor marketed by Pfizer for the treatment of advanced breast cancer with germline BRCA mutations. Talazoparib is similar to the first in class PARP inhibitor, olaparib.
|
Classification | Small molecule |
Drug class | poly-ADP-ribose polymerase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | Cn1ncnc1[C@H]1c2n[nH]c(=O)c3cc(F)cc(c23)N[C@@H]1c1ccc(F)cc1 |
PDB | — |
CAS-ID | 1207454-56-5 |
RxCUI | — |
ChEMBL ID | CHEMBL3137320 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB11760 |
UNII ID | 9QHX048FRV (ChemIDplus, GSRS) |